Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144442 · ClinicalTrials.gov registry record · NA
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01144442 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 10 participants.
The verdict
NCT01144442, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an open-label, pilot study in patients with a diagnosis of recurrent ovarian, fallopian tube or primary peritoneal carcinoma who have undergone standard cytoreductive surgery following by adjuvant chemotherapy. It is expected that this first surgery was optimal - as defined as no residual tumor \> or = 1 centimeter. Patient has clinical evidence of a first recurrence. The patient undergoes surgery and isotonic normal saline (perfusate) heated and administered into the abdomen, followed by hyperthermic intraperitoneal chemotherapy infusion (HIPC) administering carboplatin (chemotherapy). Six weeks after surgery patients will receive adjuvant chemotherapy with Paclitaxel and Carboplatin for 6 cycles.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- PROCEDURE Surgery
- DRUG Hyperthermic intraperitoneal chemotherapy with Carboplatin
- OTHER Isotonic saline (perfusate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07-27 |
| Est. Completion | 2015-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144442
The ClinicalTrials.gov registry entry for NCT01144442 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01144442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144442 about?
NCT01144442 is a clinical study titled "WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer". This is an open-label, pilot study in patients with a diagnosis of recurrent ovarian, fallopian tube or primary peritoneal carcinoma who have undergone standard cytoreductive surgery following by adjuvant chemotherapy. It is expected that this first surgery was optimal - as defined as no residual tu...
What is the current status of trial NCT01144442?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2010-07-27. Estimated completion is 2015-05-01.
What interventions are being tested in trial NCT01144442?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Surgery (PROCEDURE), Hyperthermic intraperitoneal chemotherapy with Carboplatin (DRUG), Isotonic saline (perfusate) (OTHER).
Who is sponsoring clinical trial NCT01144442?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.